{"id":"W4403202763","doi":"10.1016/s2666-5247(24)00163-0","title":"Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Microbe","topic":"Viral Infections and Outbreaks Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Nova Scotia Health Authority; Izaak Walton Killam Health Centre; Dalhousie University; Public Health Agency of Canada","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; Defense Threat Reduction Agency; Battelle; Canadian Immunization Research Network; Leidos; Frederick National Laboratory for Cancer Research; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; NHLBI Division of Intramural Research; Public Health Agency of Canada; Public Health Agency","keywords":"Medicine; Ebola virus; Booster dose; Vaccination; Ebola vaccine; Immunogenicity; Clinical trial; Booster (rocketry); Internal medicine; Randomized controlled trial; Antibody; Pediatrics; Immunization; Disease; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006223198,0.002655029,0.004146249,0.0006663434,0.0006487425,0.001796502,0.001529802,0.003840818,0.008212925],"category_scores_gemma":[0.005524552,0.001110833,0.002244909,0.0005497697,0.001923648,0.002171929,0.0006795586,0.003504353,0.001472581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001069999,"about_ca_system_score_gemma":0.001848459,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006888562,"about_ca_topic_score_gemma":0.0009763764,"domain_scores_codex":[0.9972907,0.001564991,0.0001799101,0.0004425329,0.0002111496,0.0003107097],"domain_scores_gemma":[0.9966286,0.001125733,0.0008328533,0.0003422953,0.0003012087,0.0007692968],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9886778,0.006298295,0.0001970457,0.000298663,0.0002412664,0.00001326107,0.00003737763,0.00009337911,0.001013158,0.00003344106,0.000166124,0.002930153],"study_design_scores_gemma":[0.9180933,0.08040572,0.0006450634,0.00002423698,0.0001523725,0.00001279677,0.00001042476,0.0001649966,0.0001755089,0.00006711022,0.0002393264,0.000009141731],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9794161,0.003051154,0.001019401,0.0005807611,0.0007404264,0.01249781,0.001160063,0.0001158932,0.001418302],"genre_scores_gemma":[0.9642702,0.002201578,0.003331021,0.001106924,0.0009243393,0.02375875,0.001014921,0.00004196068,0.00335029],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008212925,"threshold_uncertainty_score":0.03291184,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04765059518969653,"score_gpt":0.3885643690924924,"score_spread":0.3409137739027959,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}